EYPT vs SGP
EYPT: EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular edema, with the approved product DEXYCU generating minimal revenue. SGP: Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
Side-by-side fundamentals
| Metric | EYPT | SGP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $12.66 | $20.54 | |
| Market cap as of 2026-07-23 | $1.1B | $682M | |
| PEG as of 2026-07-23 | -0.08 | n/a | |
| Net margin as of 2026-07-23 | -3566.6% | n/a | |
| Gross margin as of 2026-07-23 | +76.5% | n/a | |
| Operating margin as of 2026-07-23 | -3700.9% | n/a | |
| ROE as of 2026-07-23 | -110.5% | -75.4% | SGP higher |
| ROA as of 2026-07-23 | -90.1% | -68.8% | SGP higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -86.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -8.8% | n/a | |
| Beta as of 2026-07-23 | 1.66 | 0.97 | |
| 1-year return as of 2026-07-22 close | +21.1% | -23.2% | EYPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.